Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 0.51
NYMX's Cash to Debt is ranked lower than
85% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. NYMX: 0.51 )
Ranked among companies with meaningful Cash to Debt only.
NYMX' s 10-Year Cash to Debt Range
Min: 0.25  Med: 10000.00 Max: No Debt
Current: 0.51
Equity to Asset -3.34
NYMX's Equity to Asset is ranked lower than
99% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NYMX: -3.34 )
Ranked among companies with meaningful Equity to Asset only.
NYMX' s 10-Year Equity to Asset Range
Min: -7.82  Med: 0.32 Max: 1
Current: -3.34
-7.82
1
F-Score: 4
Z-Score: -146.42
M-Score: 20.37
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -10.60
NYMX's Operating margin (%) is ranked higher than
63% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. NYMX: -10.60 )
Ranked among companies with meaningful Operating margin (%) only.
NYMX' s 10-Year Operating margin (%) Range
Min: -20470.59  Med: -1106.78 Max: -145.43
Current: -10.6
-20470.59
-145.43
Net-margin (%) -8.83
NYMX's Net-margin (%) is ranked higher than
63% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. NYMX: -8.83 )
Ranked among companies with meaningful Net-margin (%) only.
NYMX' s 10-Year Net-margin (%) Range
Min: -20570.59  Med: -1134.05 Max: -146.14
Current: -8.83
-20570.59
-146.14
ROA (%) -43.46
NYMX's ROA (%) is ranked lower than
65% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. NYMX: -43.46 )
Ranked among companies with meaningful ROA (%) only.
NYMX' s 10-Year ROA (%) Range
Min: -557.61  Med: -123.34 Max: -71.12
Current: -43.46
-557.61
-71.12
ROC (Joel Greenblatt) (%) -3048.08
NYMX's ROC (Joel Greenblatt) (%) is ranked lower than
74% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. NYMX: -3048.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYMX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -51962.16  Med: -22080.95 Max: -151.71
Current: -3048.08
-51962.16
-151.71
Revenue Growth (3Y)(%) -7.20
NYMX's Revenue Growth (3Y)(%) is ranked lower than
58% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NYMX: -7.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYMX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: 115.4
Current: -7.2
0
115.4
EBITDA Growth (3Y)(%) -23.50
NYMX's EBITDA Growth (3Y)(%) is ranked lower than
75% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. NYMX: -23.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYMX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -23.5  Med: 0.00 Max: 24.6
Current: -23.5
-23.5
24.6
EPS Growth (3Y)(%) -24.30
NYMX's EPS Growth (3Y)(%) is ranked lower than
70% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. NYMX: -24.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYMX' s 10-Year EPS Growth (3Y)(%) Range
Min: -24.3  Med: -1.80 Max: 23.3
Current: -24.3
-24.3
23.3
» NYMX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

NYMX Guru Trades in Q4 2013

Jim Simons 43,300 sh (+21.97%)
» More
Q1 2014

NYMX Guru Trades in Q1 2014

Jim Simons 26,506 sh (-38.79%)
» More
Q2 2014

NYMX Guru Trades in Q2 2014

Jim Simons 28,000 sh (+5.64%)
» More
Q3 2014

NYMX Guru Trades in Q3 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NYMX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 20.31
NYMX's P/S is ranked lower than
63% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. NYMX: 20.31 )
Ranked among companies with meaningful P/S only.
NYMX' s 10-Year P/S Range
Min: 4.14  Med: 187.75 Max: 729
Current: 20.31
4.14
729
Current Ratio 0.39
NYMX's Current Ratio is ranked lower than
95% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. NYMX: 0.39 )
Ranked among companies with meaningful Current Ratio only.
NYMX' s 10-Year Current Ratio Range
Min: 0.12  Med: 0.59 Max: 42.02
Current: 0.39
0.12
42.02
Quick Ratio 0.35
NYMX's Quick Ratio is ranked lower than
95% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. NYMX: 0.35 )
Ranked among companies with meaningful Quick Ratio only.
NYMX' s 10-Year Quick Ratio Range
Min: 0.09  Med: 0.57 Max: 42.02
Current: 0.35
0.09
42.02
Days Inventory 136.46
NYMX's Days Inventory is ranked lower than
57% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 118.28 vs. NYMX: 136.46 )
Ranked among companies with meaningful Days Inventory only.
NYMX' s 10-Year Days Inventory Range
Min: 8.39  Med: 51.93 Max: 178.05
Current: 136.46
8.39
178.05
Days Sales Outstanding 1.82
NYMX's Days Sales Outstanding is ranked higher than
97% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. NYMX: 1.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
NYMX' s 10-Year Days Sales Outstanding Range
Min: 1.61  Med: 51.10 Max: 997.76
Current: 1.82
1.61
997.76

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.09
NYMX's Price/Median PS Value is ranked higher than
98% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. NYMX: 0.09 )
Ranked among companies with meaningful Price/Median PS Value only.
NYMX' s 10-Year Price/Median PS Value Range
Min: 0.03  Med: 0.91 Max: 3.11
Current: 0.09
0.03
3.11
Earnings Yield (Greenblatt) (%) -0.30
NYMX's Earnings Yield (Greenblatt) (%) is ranked higher than
71% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. NYMX: -0.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NYMX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -46.2  Med: 0.00 Max: 0
Current: -0.3
-46.2
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NY2.Germany,
Nymox Pharmaceutical Corp was incorporated under the Canada Business Corporations Act in May 1995. The Company is a biopharmaceutical corporation engaged in research and development of diagnostics and drugs for brain disorders and diseases of the aged with an emphasis on Alzheimer's disease. It has three proprietary products on the market, and a significant R&D pipeline of products in development for the treatment of such conditions and diseases as BPH, prostate cancer, Alzheimer's disease or AD, E. coli O157; H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications. The Company also has U.S. and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's products include: NicAlert, TobacAlert and AlzheimAlert. The Company has developed and markets NicAlert and TobacAlert, test strips for determining whether a person is using tobacco products or has been recently exposed to second-hand smoke. It has also developed AlzheimAlert, a proprietary urine assay that can aid physicians in the diagnosis of Alzheimer's disease. The Company is also developing NX-1207, treatments for BPH and prostate and liver cancer. It is also developing NXC-4720, novel antibacterial agents for the treatment of E. coli O157 bacterial contamination in meat and other food and drink products. Its AlzheimAlert test is certified with a CE Mark, making the device eligible for sale in the European Union. The Company's competitors include: Eli Lilly and Company, GE Healthcare, Athena Diagnostics, Inc., Fujirebio Europe NV, Amorfix Life Sciences Ltd, LabCorp, Quest Diagnostics, OraSure Technologies Inc., Abraxis LLC, Roche Diagnostics, Abbott and Diagnostic Products Corporation.
» More Articles for NYMX

Headlines

Articles On GuruFocus.com
NYMOX 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and K Jan 23 2015 
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceut Dec 02 2014 
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Nymox Pharmaceutical Dec 01 2014 

More From Other Websites
Nymox Announces Appointment of James G. Robinson to Board of Directors Jul 30 2015
Nymox Pharmaceutical (NYMX) Stock Higher on Positive Test Results Jul 28 2015
Nymox July 27 Webcast of New BPH Clinical Trial Results Posted Today Online Jul 28 2015
Nymox Appoints Cutler & Co. as Auditor Jul 28 2015
Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans... Jul 28 2015
Nymox Pharmaceutical Corporation (NYMX) Jumps On News Of Study Results Jul 27 2015
Can Nymox Sustain This Massive Rally? Jul 27 2015
Market Update: Monday's Mid-Day Movers, China's Stock Market Crash And More Jul 27 2015
Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans... Jul 27 2015
Nymox Appoints Cutler & Co. as Auditor Jul 16 2015
Nymox Announces Appointment of Erik Danielsen as CFO Jul 13 2015
Nymox Announces Appointment of Erik Danielsen as CFO Jul 13 2015
Nymox Announces $850,000 Financing Jun 22 2015
Nymox Announces $850,000 Financing Jun 16 2015
Nymox Announces New Prostate Cancer Clinical Trial Results May 19 2015
Nymox Reports First Quarter 2015 Financial Results May 19 2015
Nymox Reports First Quarter 2015 Financial Results May 15 2015
Nasdaq stocks posting largest volume increases Apr 29 2015
Nymox Pharmaceuticals (NYMX) Stock Drops Today Following Monday's Climb Apr 21 2015
Nymox Pharmaceuticals (NYMX) Stock Spikes Today on Prostate Cancer Trial Data Apr 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK